<DOC>
	<DOCNO>NCT01109056</DOCNO>
	<brief_summary>This study evaluate safety efficacy Cyclosporine Ophthalmic Emulsion 0.05 % ( RESTASISÂ® ) patient primary pterygium ( abnormal growth surface eye ) .</brief_summary>
	<brief_title>Safety Efficacy Cyclosporine Ophthalmic Emulsion Patients With Primary Pterygium</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Have pterygium least one eye previously remove surgery Uncontrolled systemic disease Active eye disease Current anticipate use topical eye medication artificial tear . Anticipated wear contact lens</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>